Duchenne Muscular Dystrophy Market to Expand from USD 2.2 Billion in 2023 to USD 7.4 Billion by 2034 – Analysis by Transparency Market Research, Inc.
13. Dezember 2024 10:08 ET
|
Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc., Dec. 13, 2024 (GLOBE NEWSWIRE) -- The global Duchenne muscular dystrophy market (デュシェンヌ型筋ジストロフィー市場) was valued at US$ 2.2 billion in 2023 and...
Santhera gibt die Zulassung von AGAMREE® (Vamorolone) zur Behandlung von Duchenne-Muskeldystrophie durch Chinas NMPA bekannt
11. Dezember 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
Chinas National Medical Products Administration (NMPA) hat AGAMREE® für die Behandlung von Duchenne-Muskeldystrophie bei Patienten ab 4 Jahren zugelassenMit dieser Zulassung ist AGAMREE die erste und...
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
11. Dezember 2024 01:00 ET
|
Santhera Pharmaceuticals Holding AG
China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and olderThis approval makes AGAMREE the first and...
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
13. November 2024 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
06. November 2024 16:12 ET
|
Catalyst Pharmaceuticals, Inc.
Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance...
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
24. September 2024 07:30 ET
|
Wave Life Sciences USA, Inc.
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two...
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
12. August 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
Designation highlights significant unmet needs in DMD; dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 are on track for 3Q 2024 In previous Part A trial, WVE-N531...
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
24. Juli 2024 08:05 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Muscular Dystrophy Association Applauds Expanded US FDA Approval of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy Patients Ages 4 and Above
20. Juni 2024 18:42 ET
|
Muscular Dystrophy Association
New York, June 20, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the U.S. Food and Drug Administration’s expanded approval of ELEVIDYS (delandistrogene...
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
01. Mai 2024 08:00 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...